资讯

The Trump administration said Tuesday it will limit approval for seasonal COVID-19 shots to seniors and others at high risk ...
The US Food and Drug Administration has fully approved a new COVID vaccine option specifically targeting high-risk individuals, including seniors. The protein-based Nuvaxovid vaccine, produced by ...
The U.S. Food and Drug Administration on Tuesday said it plans to require new clinical trials for approval of annual COVID-19 ...
In the NEJM article, the FDA notes that covid booster uptake has been low in the US, with less than a quarter of people ...
Details of the new rules for COVID-19 vaccine approvals were also outlined in an article published by The New England Journal ...
The VRBPAC meeting comes the week after the World Health Organization (WHO) recommended that members consider using ...
Novavax's shot is now fully approved in the U.S. Since 2022, the vaccine has been used under an emergency use authorization.
The new framework was well-received by biopharma analysts, who say it “largely formalizes” current COVID-19 vaccination ...
COVID-19 shots for healthy younger adults and children will no longer be routinely approved under a major new policy shift unveiled Tuesday by the Trump administration.